KeyBanc Lifts Solvay to Overweight as Firm Sees Improved MedTech Backdrop for 2026
KeyBanc Capital Markets has raised its rating on Solvay (NYSE:SOLV) from Sector Weight to Overweight in its 2026 Medical Technology outlook. The bank highlights a narrowing of the sector's valuation premium, stronger underlying demand signs in late 2025, and an uptick in M&A as supporting a selective stock-picking strategy. The report also names se…